Supernus Pharmaceuticals, INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersRockville, MD
US patents79
SAM.gov UEIYGWZHL8KYAM8
CAGE code6WHD6
Incorporated inDE
LEI549300GRM36VBKISYJ58
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
79 US patents granted 2007–2025, 14 of them in the five years to SEP 2025.
Pharmaceuticals 68Organic fine chemistry 10Biotechnology 1
- Derivatives of substituted morpholines and uses thereofUS 12,215,097 · granted FEB 4, 2025
- Method of treatment of attention deficit/hyperactivity disorder (ADHD)US 12,121,523 · granted OCT 22, 2024
- Process of making derivatives of substituted morpholinesUS 11,964,951 · granted APR 23, 2024
- Derivatives of substituted morpholines and uses thereofUS 11,919,889 · granted MAR 5, 2024
- Method of treatment of CNS disordersUS 11,911,368 · granted FEB 27, 2024
Newest 5 shown · Granted to Supernus Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Supernus Pharmaceuticals, INC | Rockville | MD | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.